Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB571 Monotherapy in MET-aberrant Advanced or Metastatic NSCLC (Phase II)
CTR20255006Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SKB571 in non-small cell lung cancer (NSCLC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
SKB571
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20255006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255006.